Non-Alcoholic Steatohepatitis Clinical Trials Market Unveils Forecast from 2022 to 2032-FMI Study

Non-Alcoholic Steatohepatitis Clinical Trials Market

The global non-alcoholic steatohepatitis clinical trials market size is expected to be valued US$ 2.6 billion in 2022, according to Future Market Insights. On the other hand, a substantial expansion in the market is anticipated between 2022 and 2032, with a predicted growth rate of 7%, surpassing the historical increase. With a CAGR of 11.2% from 2022 to 2032, Phase 3 is predicted to be the segment in the Non-Alcoholic Steatohepatitis Clinical Trials Market that generates the most income.

Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-15802

Market for Non-Alcoholic Steatohepatitis Clinical Trials from 2017 to 2021 in terms of revenue In contrast to the Demand Forecast for 2022 to 2032

According to Future Market Insights, a market research and competitive intelligence provider, the market value of this disease increased at a compound annual growth rate (CAGR) of about 6.2% between 2017 and 2021, with the United States, the United Kingdom, China, and Japan accounting for a sizable portion of the global market.

Furthermore, technological advancements, an ageing population, an increase in the prevalence of chronic diseases, and an increase in surgical procedures are key drivers of the expansion. As a result, the market for clinical trials for non-alcoholic steatohepatitis is predicted to increase at a CAGR.

How did the market for Non-Alcohol Steatohepatitis Clinical Trials perform during the pandemic?

Trials were suspended due to decreased patient participation in clinical research and supply chain issues induced by the epidemic. In contrast, virtual participants and COVID-compliant screening permitted select organisations to complete the trials. Novartis, for example, conducted a phase two trial of a specific medication for non-alcoholic steatohepatitis after the drug was designated as a breakthrough treatment in the United States. In 2021, semaglutide will be started in patients with non-alcoholic steatohepatitis (NASH) in phase 3a. The results of a phase two proof-of-concept investigation in NASH were reported by Novo Nordisk and Gilead Sciences. In the United States, NASH is the second most common reason for a liver transplant. NASH has also been associated to hepatocellular carcinoma.

The results of a phase two proof-of-concept study in NASH were revealed by Nordisk and Gilead Sciences. The second most common reason for liver transplants in the US is NASH. Several studies have found a connection between NASH and hepatocellular cancer growth.

Analysis by country

The USA Clinical Trials for Non-Alcoholic Steatohepatitis: Market Research

NAFLD is one of the most common chronic liver diseases in the United States. In the United States, approximately 20% of adults are estimated to have NASH, while approximately 25% are thought to have NAFLD. Given these troubling statistics, the Non-Alcoholic Steatohepatitis Clinical Trials market in the United States is expected to grow at a 7.5% CAGR from 2022 to 2032, reaching a value of US$ 1.9 billion.

Because to pathologist bias, it can be difficult to divide patients into discrete fibrosis phases in NASH trials. Sagimet Biosciences is using digital histopathology in its Stage IIb non-alcoholic steatohepatitis (NASH) inquiry to achieve more accurate and consistent biopsy analysis. Histological imaging of biopsy samples is used in digital pathology for NASH, which is then analysed using artificial intelligence (AI) to detect fibrosis abnormalities. TVB-2640 is being studied in the Phase IIb FASCINATE-2 trial (NCT04906421) by Sagimet and HistoIndex, a Singapore-based diagnostic firm.

Unlock exclusive insights with our expert analysts:
https://www.futuremarketinsights.com/ask-question/rep-gb-15802

Market Segments Covered in Non-Alcoholic Steatohepatitis Clinical Trials Market Analysis

By Study Design:

• Interventional
• Observational
• Expanded Access

By Phase:

• Phase 1
• Phase 2
• Phase 3
• Phase 4

By Region:

• North America
• Latin America
• Asia-Pacific (APAC)
• Middle East and Africa (MEA)
• Europe

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube